Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2017

Michael Heller's Biography



Michael Heller, Professor, University of California San Diego

Michael J. Heller received his Ph.D. in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. Dr. Heller was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) from 1976 to 1984. During that period he carried out bioengineering work on chemiluminescent, fluorescent and FRET DNA probe diagnostics and recombinant DNA engineering work on plants, algae and photosynthetic bacteria for energy and chemical production. He also oversaw the Amoco sponsored research projects (>$5 million) at Cetus Corporation on related recombinant DNA work for energy and chemical production and thermophilic enzymes. Dr. Heller was Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987. He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989. He was a co-found of Nanotronics and Nanogen, and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of microelectronic DNA array technology for clinical genotyping applications. Dr. Heller is now a Professor in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He has also recently co-founded a new company called Biological Dynamics which will be developing new cancer diagnostic technology. Dr. Heller has extensive industrial experience in biotechnology, biomedical and clinical diagnostic devices and nanotechnology; with particular expertise in the areas of DNA probe diagnostics, DNA synthesis, fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanocomponents. Dr. Heller has a respectable publication record, and has been an invited speaker to a large number of scientific conferences and meetings related to DNA microarrays, biosensors, lab-on-a-chip devices, bio-MEMS and nanotechnology. He has over 50 issued US patents related to microelectronic chips, microarrays and integrated devices for DNA hybridization, miniaturized sample to answer diagnostic devices, biosensors, genomics, proteomics, nanotechnology and nanofabrication, nano-based DNA optical storage and for fluorescent energy transfer in DNA nanostructures. Dr. Heller has been a panel member for the White House (OSTP) National Nanotechnology Initiative 1999/2000; the NAS (NAE) Review of National Nanotechnology Initiative 2001-2002; the NAS(NAE) – Engineer for the 2020 - 2001/2002; and has also been involved in a number of NSF Nanotechnology Workshops.

Michael Heller Image

Cell Free DNA and Exosome Biomarkers for Liquid Biopsy Cancer Diagnostics and Early Cancer Detection

Friday, 6 October 2017 at 14:30

Add to Calendar ▼2017-10-06 14:30:002017-10-06 15:30:00Europe/LondonCell Free DNA and Exosome Biomarkers for Liquid Biopsy Cancer Diagnostics and Early Cancer DetectionLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Cell free (cf) DNA and exosomal RNA and proteins are now accepted as important biomarkers for liquid biopsy cancer diagnostics, and may also be used for early cancer detection. Nevertheless, the isolation of these biomarkers from patient samples requires relatively complex, time consuming and expensive procedures which greatly limits their practical use for most cancer diagnostic applications. New AC electrokinetic (ACE) microarray/chip devices (Biological Dynamics, La Jolla, CA) now allow 15-20-minute isolation of cancer related cf-DNA, exosomal RNA and protein biomarkers from 20-50ul of blood, plasma or serum. After isolation of the biomarkers, specific fluorescent dyes can be used first to simultaneously detect the different biomarker levels directly on the chip (in-situ). In a subsequent step, immunofluorescent analysis can be carried out to identify specific protein biomarkers on the exosomes. Finally, the cf-DNA and RNA (mRNAs and miRNAs release from the exosomes) can be eluted from the DEP chip, and PCR and sequencing analysis carried out to identify the cancer-related point mutations and other polymorphisms, as well as to further verify the tissue origin of the biomarkers. For glioblastoma exosomes isolated from plasma, exosome-specific surface and interior proteins CD63 and TSG101 could be detected by immuno-fluorescence, and mutated EGFRvlll mRNA was detected by RT-PCR. Exosomal related protein biomarker Glypican-1 could be isolated from pancreatic cancer patient plasma samples by ACE and then detected on-chip by immunofluorescence, and Kras mutations detected in the eluted cf-DNA. Similar results are being obtained for prostate, breast, lung and brain cancer, as well as for TBI patient samples. Thus, ACE technology represents a powerful new minimally invasive technology for cancer diagnostics that is particularly well suited for the rapid isolation of cell free nucleic acid and exosome biomarkers. The technology is setting the stage for seamless sample to answer liquid biopsy, cancer patient therapy monitoring and ultimately for early disease detection.


Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com